European Commission grants marketing authorization to AstraZeneca's Lynparza

18 December 2014
astrazeneca-large

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has received marketing authorization from the European Commission for Lynparza (olaparib) capsules for certain kinds of ovarian, fallopian tube, or primary peritoneal cancer.

It has been approved as the first therapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy.

Olaparib exploits tumor DNA repair pathway deficiencies to preferentially kill cancer cells. A Phase II study showed that olaparib maintenance therapy significantly prolonged progression-free survival compared with placebo in BRCA-mutated ovarian cancer, with progression-free survival standing at a median of 11.2 months in the olaparib arm and 4.3 months in placebo.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical